{"id":"W2036143910","doi":"10.1158/1535-7163.targ-13-pr09","title":"Abstract PR09: Synergistic activity of CRLX101, a nanopharmaceutical in Phase II clinical trials, with antiangiogenic therapies mediated through HIF-1alpha inhibition: A translational research program.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Cancer research; Bevacizumab; Camptothecin; Angiogenesis; Metastasis; Cancer; Ovarian cancer; Tumor hypoxia; Gemcitabine; Oncology; Pharmacology; Internal medicine; Chemotherapy; Biology; Radiation therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001790956,0.0003268541,0.0006889319,0.0001292997,0.000135645,0.00004777165,0.0002500316,0.0003797906,0.0002152553],"category_scores_gemma":[0.00011275,0.0002701917,0.0003450736,0.0005674948,0.0006490751,0.00002734415,0.00006820748,0.0005017414,0.000005074584],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003650108,"about_ca_system_score_gemma":0.0007115905,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002428812,"about_ca_topic_score_gemma":0.0001816027,"domain_scores_codex":[0.9963301,0.0009480534,0.0008569499,0.0006320823,0.0006450257,0.0005877699],"domain_scores_gemma":[0.9984655,0.0001976361,0.0002825834,0.0004591288,0.0004410497,0.0001540431],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001701308,0.00184548,0.0002281917,0.00006464585,0.0006896145,0.00001030264,0.0002797968,0.00006188828,0.9011588,0.0001139772,0.000196245,0.09364974],"study_design_scores_gemma":[0.01852606,0.002858706,0.006105768,0.0001936299,0.0004091142,0.00001521679,0.0001443933,0.0006726414,0.8342819,0.000855963,0.1351413,0.0007953874],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.969519,0.02497058,0.001491504,0.001569486,0.0003482825,0.001767482,0.0001188465,0.00002794606,0.0001869285],"genre_scores_gemma":[0.9908477,0.006273327,0.000928601,0.000480384,0.000616651,0.0006163584,0.0001233197,0.00006488708,0.00004877142],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.134945,"threshold_uncertainty_score":0.999975,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1639044074039281,"score_gpt":0.4720174431728413,"score_spread":0.3081130357689132,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}